2025-05-02 18:53:41
Latest Post
LKP Securities Ltd consolidated Q4FY25 profit up QoQ at Rs. 2.69 crore
Krystal Integrated Services Ltd Q4 FY2025 consolidated net profit up at Rs. 11.84 crores
ELANTAS Beck India Ltd Q1 CY2025 PAT higher QoQ at Rs. 32.86 crores
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Stock Report
Glenmark Pharmaceuticals Ltd consolidated Q3FY23 net profit higher at Rs. 272.57 crores
Posted On : 2023-02-12 15:42:06( TIMEZONE : IST )
Glenmark Pharmaceuticals Limited has reported Consolidated financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 3540.273 crores during the period ended December 31, 2022 as compared to Rs. 3472.677 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. 272.579 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 260.440 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. 9.66 for the period ended December 31, 2022 as compared to Rs. 9.23 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹3540.273 crs | ₹3472.677 crs |  1.95% |
| Net Profit | ₹272.579 crs | ₹260.440 crs | 4.66% |
| EPS | ₹9.66 | ₹9.23 | 4.66% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.3540.273 crores during the period ended December 31, 2022 as compared to Rs.3187.309 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.272.579 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.221.902 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.9.66 for the period ended December 31, 2022 as compared to Rs.7.86 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹3540.273 crs | ₹3187.309 crs | 11.07% |
| Net Profit | ₹272.579 crs | ₹221.902 crs | 22.84% |
| EPS | ₹9.66 | ₹7.86 | 22.90% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.9973.394 crores during the 9 Months period ended December 31, 2022 as compared to Rs.9345.228 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.725.547 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.786.126 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.25.71 for the 9 Months period ended December 31, 2022 as compared to Rs.27.86 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹9973.394 crs | ₹9345.228 crs | 6.72% |
| Net Profit | ₹725.547 crs | ₹786.126 crs |  -7.71% |
| EPS | ₹25.71 | ₹27.86 | -7.72% |
Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 399.85 as compared to the previous close of Rs. 394.20. The total number of shares traded during the day was 25255 in over 1614 trades.
The stock hit an intraday high of Rs. 403.15 and intraday low of 388.00. The net turnover during the day was Rs. 10029059.00.
